Table 7b. Antiplatelet Therapy: Selected Clinical Data

• Laboratory-confirmed SARS-CoV-2 infection
• Any 1 of the following:
  • D-dimer level ≥2 times ULN
  • Aged 60–84 years
  • Aged <60 years with oxygen requirement >2 L/min, HTN, DM, eGFR <60 mL/min, CVD, or BMI ≥35

Key Exclusion Criteria

• Required HFNC oxygen ≥20 L/min, NIV, MV, ECMO, vasopressors, or inotropes
• ≥72 hours since hospital admission

Interventions

• Therapeutic dose of heparin plus P2Y12 inhibitor for 14 days or until discharge (n = 293)
• Therapeutic dose of heparin (usual care arm) (n = 269)

Primary Endpoints

• Number of organ support-free days by Day 21
• Major bleeding event by Day 28

Key Secondary Endpoint

• Major thrombotic event or death by Day 28

Participant Characteristics

• Mean age 53 years; 42% women; 62% White
• HTN: 43% in P2Y12 inhibitor arm vs. 55% in usual care arm
• 65% on glucocorticoids; 52% on RDV; 3% on IL-6 inhibitors; 14% on aspirin
• Median duration of P2Y12 inhibitor treatment: 6 days
  • 63% received ticagrelor; 37% received clopidogrel

Primary Outcomes

• Median number of organ support-free days by Day 21: 21 in both arms (aOR 0.83; 95% CrI, 0.55–1.25; posterior probability of futility 96%)
• Major bleeding events by Day 28: 2.0% in P2Y12 inhibitor arm vs. 0.7% in usual care arm (aOR 3.31; 95% CI, 0.64–17.2; P = 0.15)

Secondary Outcome

• Major thrombotic event or death by Day 28: 6.1% in P2Y12 inhibitor arm vs. 4.5% in usual care arm (aOR 1.42; 95% CI, 0.64–3.13)

• Open-label study
• Study stopped early for futility
• Different P2Y12 inhibitors used
• Median duration of P2Y12 inhibitor use was 6 days, which may not be sufficient to observe effects.

Interpretation

• Among hospitalized patients with COVID-19 who were not critically ill, adding a P2Y12 inhibitor to a therapeutic dose of heparin did not increase the number of organ support-free days.
• Major bleeding events occurred infrequently during the study. The number of patients who experienced a major bleeding event was not significantly different between the arms.

• Clinically suspected or laboratory-confirmed SARS-CoV-2 infection

Key Exclusion Criteria

• Hypersensitivity to aspirin
• Recent history of major bleeding events
• Currently receiving aspirin or another antiplatelet treatment

Interventions

• Aspirin 150 mg once daily until discharge (n = 7,351)
• SOC alone (n = 7,541)

Primary Endpoint

• All-cause mortality at 28 days

Key Secondary Endpoints

• Progression to MV or death at 28 days
• Major bleeding or thrombotic events at 28 days

Participant Characteristics

• Mean age 59 years; 62% men; 75% White
• 97% had laboratory-confirmed SARS-CoV-2 infection
• At baseline:
  • 33% on NIV or MV
  • 34% on intermediate- or therapeutic-dose LMWH
  • 60% on standard-dose LMWH
  • 7% received no thromboprophylaxis
• 94% on corticosteroids; 26% on RDV; 13% on tocilizumab; 6% on baricitinib

Primary Outcome

• All-cause mortality at 28 days: 17% in both arms (rate ratio 0.96; 95% CI, 0.89–1.04; P = 0.35)

Secondary Outcomes

• Progression to MV or death at 28 days: 21% in aspirin arm vs. 22% in SOC arm (risk ratio 0.96; 95% CI, 0.90–1.03)
• Major bleeding events at 28 days: 1.6% in aspirin arm vs. 1.0% in SOC arm (P = 0.0028)
• Thrombotic events at 28 days: 4.6% in aspirin arm vs. 5.3% in SOC arm (P = 0.07)

• Because of open-label design, reporting of thrombotic and major bleeding events may have influenced treatment allocation.

Interpretation

• In hospitalized patients with COVID-19, the use of aspirin was not associated with reductions in 28-day mortality or the risk of progressing to MV or death.

• Clinically suspected or laboratory-confirmed SARS-CoV-2 infection
• Within 48 hours of ICU admission

Key Exclusion Criteria

• Bleeding risk sufficient to contraindicate antiplatelet therapy
• CrCl <30 mL/min
• Receiving antiplatelet therapy or NSAID

Interventions

• 1 of the following plus anticoagulation for 14 days or until hospital discharge, whichever came first:
  • Aspirin 75–100 mg once daily (n = 565)
  • P2Y12 inhibitor (n = 455)
  • No antiplatelet therapy (control arm) (n = 529)

Primary Endpoint

• Number of organ support-free days by Day 21

Key Secondary Endpoints

• Survival to hospital discharge
• Survival to Day 90
• Major bleeding event by Day 14

Participant Characteristics

• Mean age 57 years; 34% women; 77% White
• At baseline, 98% on LMWH:
  • 19% on low-dose LMWH
  • 59% on intermediate-dose LMWH
  • 12% on therapeutic-dose LMWH
• 98% on steroids; 21% on RDV; 44% on tocilizumab; 11% on sarilumab
• In P2Y12 inhibitor arm, 88.5% received clopidogrel, 1.3% received ticagrelor, 1.3% received prasugrel, and 8.8% received an unknown P2Y12 inhibitor

Primary Outcome

• Data from aspirin and P2Y12 inhibitor arms were pooled and reported as “pooled antiplatelet arm” in final analysis:
  • Median number of organ support-free days by Day 21: 7 in pooled antiplatelet arm and control arm (aOR 1.02; 95% CrI, 0.86–1.23; posterior probability of futility 96%)
    

Secondary Outcomes

• Survival to hospital discharge: 71.5% in pooled antiplatelet arm vs. 67.9% in control arm (median-adjusted OR 1.27; 95% CrI, 0.99–1.62; adjusted absolute difference 5%; 95% CrI, -0.2% to 9.5%; 97% posterior probability of efficacy)
• Survival to Day 90: 72% in pooled antiplatelet arm vs. 68% in control arm (HR with pooled antiplatelets 1.22; 95% CrI, 1.06–1.40; 99.7% posterior probability of efficacy)
• Major bleeding event by Day 14: 2.1% in pooled antiplatelet arm vs. 0.4% in control arm (aOR 2.97; 95% CrI, 1.23–8.28; posterior probability of harm 99.4%)

• Open-label study
• Different P2Y12 inhibitors used
• Trial stopped for futility. Because equivalence for aspirin and P2Y12 inhibitor arms was reached, these arms were pooled for analyses.

Interpretation

• In critically ill patients with COVID-19, the use of aspirin or a P2Y12 inhibitor did not reduce the number of organ support-free days or in-hospital mortality.
• Patients in the pooled antiplatelet arm had more major bleeding events than those in the control arm, but they had improved survival over 90 days.

• Aged ≥18 years
• Acute SARS-CoV-2 infection
• Required ICU-level care for ≤96 hours prior to randomization

• Ongoing or planned use of a therapeutic dose of anticoagulation or dual antiplatelet therapy
• High risk of bleeding
• History of HIT
• Ischemic stroke within 2 weeks

• Clopidogrel 300 mg at randomization, then clopidogrel 75 mg once daily until hospital discharge or Day 28, whichever came first (n = 152)
• No clopidogrel therapy (n = 140)
• Some patients also randomized to receive a therapeutic or prophylactic dose of anticoagulation (n = 290)

• Composite of VTE or ATEs by hospital discharge or Day 28. Events included death due to VTE or ATEs, PE, clinically evident DVT, MI, ischemic stroke, systemic embolic events or acute limb ischemia, and clinically silent DVT. 

• Composite of clinically evident VTE or ATEs by hospital discharge or Day 28

• Fatal or life-threatening bleeding
• Moderate or severe bleeding

• Median age 58 years; 41% women; 71% White
• At baseline, 99% required HFNC, NIV, or MV; 15% required MV (37% required MV during the study)

• Composite of VTE or ATEs by hospital discharge or Day 28: 10% in both arms (win ratio 1.04; 95% CI, 0.54–2.01; P = 0.90)

• Composite of clinically evident VTE or ATEs by hospital discharge or Day 28: 7% in clopidogrel arm vs. 9% in no clopidogrel arm (win ratio 0.79; 95% CI, 0.38–1.65; P = 0.53)

• Fatal or life-threatening bleeding: 1.3% in clopidogrel arm vs. 1.4% in no clopidogrel arm (P = 1.00)
• Moderate or severe bleeding: 4.0% in clopidogrel arm vs. 6.4% in no clopidogrel arm (P = 0.83)

• Open-label study (adjudication committee members were blinded to the study arms)
• Stopped early because decreasing number of ICU admissions for patients with COVID-19 made recruitment difficult
• 31% discontinued clopidogrel  

• In patients with COVID-19 who required ICU-level care, clopidogrel did not reduce the incidence of thrombotic complications.